LT3380486T - Jak inhibitoriaus junginio provaistai, skirti virškinimo trakto uždegiminės ligos gydymui - Google Patents

Jak inhibitoriaus junginio provaistai, skirti virškinimo trakto uždegiminės ligos gydymui

Info

Publication number
LT3380486T
LT3380486T LTEP16808876.3T LT16808876T LT3380486T LT 3380486 T LT3380486 T LT 3380486T LT 16808876 T LT16808876 T LT 16808876T LT 3380486 T LT3380486 T LT 3380486T
Authority
LT
Lithuania
Prior art keywords
prodrugs
treatment
inflammatory disease
inhibitor compound
jak inhibitor
Prior art date
Application number
LTEP16808876.3T
Other languages
English (en)
Inventor
Ryan Hudson
Daniel D. Long
Donna A.A. Wilton
Mandy Loo
Patrick J. Brassil
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of LT3380486T publication Critical patent/LT3380486T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165Heterorings having nitrogen atoms as the only ring heteroatoms
LTEP16808876.3T 2015-11-24 2016-11-22 Jak inhibitoriaus junginio provaistai, skirti virškinimo trakto uždegiminės ligos gydymui LT3380486T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24
PCT/US2016/063254 WO2017091544A1 (en) 2015-11-24 2016-11-22 Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease

Publications (1)

Publication Number Publication Date
LT3380486T true LT3380486T (lt) 2020-05-11

Family

ID=57518004

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16808876.3T LT3380486T (lt) 2015-11-24 2016-11-22 Jak inhibitoriaus junginio provaistai, skirti virškinimo trakto uždegiminės ligos gydymui

Country Status (32)

Country Link
US (3) US10435428B2 (lt)
EP (1) EP3380486B1 (lt)
JP (2) JP6778747B2 (lt)
KR (1) KR20180080330A (lt)
CN (1) CN108290918B (lt)
AU (1) AU2016359494B2 (lt)
BR (1) BR112018010650A8 (lt)
CA (1) CA3003283A1 (lt)
CL (1) CL2018001345A1 (lt)
CO (1) CO2018005327A2 (lt)
CY (1) CY1122918T1 (lt)
DK (1) DK3380486T3 (lt)
EA (1) EA035816B1 (lt)
ES (1) ES2784523T3 (lt)
HR (1) HRP20200561T1 (lt)
HU (1) HUE049775T2 (lt)
IL (1) IL259076B (lt)
LT (1) LT3380486T (lt)
ME (1) ME03757B (lt)
MX (1) MX2018006282A (lt)
MY (1) MY189979A (lt)
NZ (1) NZ742574A (lt)
PH (1) PH12018501037A1 (lt)
PL (1) PL3380486T3 (lt)
PT (1) PT3380486T (lt)
RS (1) RS60237B1 (lt)
SG (1) SG11201803686UA (lt)
SI (1) SI3380486T1 (lt)
TW (1) TWI703147B (lt)
UA (1) UA121270C2 (lt)
WO (1) WO2017091544A1 (lt)
ZA (1) ZA201802967B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
EA035816B1 (ru) 2015-11-24 2020-08-14 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
WO2018165250A1 (en) * 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
BR112019024509A2 (pt) 2017-05-23 2020-06-23 Theravance Biopharma R&D Ip, Llc Glicuronídeo de pró-fármacos dos inibidores da janus quinase
CN110662755A (zh) * 2017-05-23 2020-01-07 施万生物制药研发Ip有限责任公司 托法替尼的硫代氨基甲酸酯前药
EP3634430A4 (en) * 2017-06-05 2021-04-14 Flagship Pioneering Innovations V, Inc. MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF
WO2019136298A1 (en) 2018-01-05 2019-07-11 Cybrexa, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
KR20190110459A (ko) * 2018-03-20 2019-09-30 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
KR20210074291A (ko) * 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
WO2020102519A1 (en) * 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease
CN113692278A (zh) 2018-12-19 2021-11-23 因赛特公司 用于治疗胃肠道疾病的jak1途径抑制剂
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220051332A (ko) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. 치료제로서의 미세소관 표적화제의 펩티드 접합체
CN114341162A (zh) 2019-07-10 2022-04-12 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021231272A1 (en) * 2020-05-14 2021-11-18 Theravance Biopharma R&D Ip, Llc Administration of gut-selective jak3 inhibitor
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
EP4232146A1 (en) * 2020-10-22 2023-08-30 Biora Therapeutics, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
EP4351584A1 (en) * 2021-06-07 2024-04-17 The Regents of the University of California Compositions and methods for treating celiac disease
US20230381185A1 (en) * 2022-05-14 2023-11-30 3-D Matrix, Ltd. Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
NZ518884A (en) 1999-12-10 2004-02-27 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
KR20180126619A (ko) 2009-10-09 2018-11-27 인사이트 홀딩스 코포레이션 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2695617B1 (en) 2009-12-23 2019-01-09 Glycomyr Inc. Vitamin D glycosides and sulfates for treating intestinal diseases
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
MX2012009074A (es) * 2010-02-05 2012-08-23 Pfizer Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
US20140357557A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US10172921B2 (en) * 2014-06-24 2019-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
EA035816B1 (ru) 2015-11-24 2020-08-14 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта
AU2016379454B2 (en) 2015-12-23 2021-01-28 The University Of British Columbia Lipid-linked prodrugs
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
AU2016359494B2 (en) 2021-01-07
US11608354B2 (en) 2023-03-21
SG11201803686UA (en) 2018-06-28
BR112018010650A8 (pt) 2019-02-26
EP3380486B1 (en) 2020-02-19
BR112018010650A2 (pt) 2018-11-13
TWI703147B (zh) 2020-09-01
US20170145044A1 (en) 2017-05-25
HUE049775T2 (hu) 2020-10-28
AU2016359494A1 (en) 2018-06-14
WO2017091544A1 (en) 2017-06-01
JP6778747B2 (ja) 2020-11-04
US10961267B2 (en) 2021-03-30
CY1122918T1 (el) 2021-10-29
UA121270C2 (uk) 2020-04-27
CO2018005327A2 (es) 2018-05-31
EA201891248A1 (ru) 2018-10-31
IL259076A (en) 2018-06-28
ME03757B (me) 2021-04-20
IL259076B (en) 2021-05-31
SI3380486T1 (sl) 2020-07-31
EP3380486A1 (en) 2018-10-03
NZ742574A (en) 2018-11-30
RS60237B1 (sr) 2020-06-30
MY189979A (en) 2022-03-22
US20190389895A1 (en) 2019-12-26
TW201720827A (zh) 2017-06-16
JP2020196742A (ja) 2020-12-10
US10435428B2 (en) 2019-10-08
HRP20200561T1 (hr) 2020-06-26
PL3380486T3 (pl) 2020-07-27
MX2018006282A (es) 2019-01-21
EA035816B1 (ru) 2020-08-14
ZA201802967B (en) 2019-04-24
PH12018501037A1 (en) 2019-01-28
CL2018001345A1 (es) 2018-06-22
PT3380486T (pt) 2020-05-22
CN108290918B (zh) 2021-06-08
CA3003283A1 (en) 2017-06-01
ES2784523T3 (es) 2020-09-28
CN108290918A (zh) 2018-07-17
DK3380486T3 (da) 2020-05-18
KR20180080330A (ko) 2018-07-11
JP2019501133A (ja) 2019-01-17
US20210179655A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
ZA201802967B (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
HK1251941A1 (zh) 具有增加的生物利用度的阿伏西地前藥
IL268446A (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds that are jak inhibitors
IL250709B (en) Aminopyrimidines and their use to inhibit jak
ZA201906817B (en) Methods of treatment using a jak inhibitor compound
HUE064003T2 (hu) JAK-gátló
PL3831833T3 (pl) Sposoby wytwarzania inhibitora pi3k
EP3341364C0 (en) METHOD FOR PRODUCING A DUAL ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND
HK1256902A1 (zh) 氯犬尿氨酸的前體藥物
HK1258512A1 (zh) 芬坎法明的前藥
IL259394B (en) Reliable prodrugs in pharmaceutical compositions
IL266223A (en) Drug inhibitors of kallikrein inhibitors
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
ZA201707682B (en) Polymorphs of a pges-1 inhibiting triazolone compound
TH171939B (th) สารประกอบอะมิโนไพริมิดิล ซึ่งเป็นสารยับยั้ง jak
GB201417347D0 (en) Prodrugs of delanzomib
GB201417348D0 (en) Prodrugs of lxazomib